Bioqube ventures, a specialist life sciences investment firm that will focus on early-stage investments launches today. Bioqube ventures is an independent new venture that aims to identify, coach and nurture new investment opportunities. The bioqube ventures team is led by Debora Dumont and Nico Vandervelpen, co-founders and Managing Partners.
Debora Dumont, Managing Partner bioqube ventures said: “Leveraging on our experience in venture capital and incubation models, bioqube ventures is well positioned to offer scientists and entrepreneurs access to funding, management, business and R&D expertise to enable early stage life sciences companies reach their full potential.”
Bioqube ventures is proud to announce it has entered into a collaboration with Janssen Pharmaceutica NV (Janssen), part of the Janssen Pharmaceutical Companies of Johnson & Johnson to manage the recently announced Johnson & Johnson Innovation, JLINX incubation model. JLINX will provide entrepreneurs with opportunities to exchange ideas and collaborate across the European life science ecosystem while accessing a unique combination of resources including venture based investment, state-of-the-art infrastructure at the Janssen campus in Beerse, Belgium and access to relevant scientific, technical and business expertise.
Nico Vandervelpen, Managing Partner bioqube ventures, said: “We are delighted to partner with JLINX to create a start-up culture that fosters creativity backed by the powerhouse that is Johnson & Johnson. In addition, we will manage the relationship with external investors with the ambition to scale-up the initiative and contribute in closing the early-stage funding gap.”
Further information on JLINX is available via jlinx.jnjinnovation.com. Entrepreneurs interested in joining the JLINX initiative can also reach out to bioqube ventures through email@example.com.
Supriya Mathur - Hume Brophy
M +44 (0)7 884 580 422